To determine whether some patients with idiopathic hypospadias have HSD3B2 mutations, we genotyped this locus in 90 patients with hypospadias (age, 6.0 ؎ 0.4 yr) and 101 healthy fertile male controls. We measured basal plasma renin activity and performed an ACTH test for determination of 17-OH-pregnenolone, 17-OH-progesterone, cortisol, dehydroepiandrosterone sulfate, and androstenedione and an human chorionic gonadotropin test for determination of androstenedione, testosterone, and dihydrotestosterone. We did not observe a clear steroidogenic pattern suggestive of 3␤-HSD deficiency in any patient. DNA was extracted from peripheral lymphocytes; and exons 1, 2, 3, and 4 were amplified by PCR and analyzed by denaturing gradient gel electrophoresis. An abnormal electrophoretic migration pattern of exon 4 was observed in five patients. Two patients had missense heterozygous mutations (S213T and S284R). In another three patients, we observed heterozygous nucleotide variants in exon 4 that did not produce a change in amino acids (A238, T259, T320). In vitro enzymatic activity was diminished by 40% and 32% in the S213T and S284R heterozygous mutations, respectively. One control exhibited a heterozygous mutation in exon 3 (V78I), which did not alter in vitro enzyme activity. In addition, we observed possible polymorphisms in intron 1 in four patients and one control. We conclude that subtle molecular abnormalities in the HSD3B2 gene may be observed in some patients with apparent idiopathic hypospadias but that this finding is uncommon. (J Clin Endocrinol Metab 89: [957][958][959][960][961][962][963][964] 2004) 
H
YPOSPADIAS IS ONE of the most frequent congenital malformations with an incidence around one per 125 to one per 300 live male births (1-3), which has apparently increased during the last decades (4, 5) . The significance of the hypospadias relates not only to its frequency but to important functional and cosmetic impairment. In this malformation, the urethral meatus is located on the ventral side of the penis proximal to the tip of the glans, from the balanopreputial sulcus to the perineal area. The urethra is formed by fusion of the urethral folds along the ventral surface of the penis, a process that occurs during the first trimester of gestation, and depends on the proper secretion and action of androgens (6) .
One important enzyme involved in the synthesis of mineralocorticoids, glucocorticoids, and sex steroids is the 3␤-hydroxysteroid dehydrogenase (3␤-HSD), which belongs to aldo-keto reductase family and is a membrane-bound protein in the endoplasmic reticulum and mitochondria (7) (8) (9) (10) . This enzyme is necessary for the conversion of pregnenolone to progesterone, 17-OH-pregnenolone (17OH Preg) to 17OH progesterone (17OH Prog), and of dehydroepiandrosterone (DHEA) to androstenedione. It catalyzes the oxidation and isomerization of 5-ene-3␤-hydroxypregnene and 5-ene-hydroxyandrostene steroid precursors into the corresponding 4-ene-ketosteroids.
In humans, there are two isoenzymes, encoded by two genes on chromosome 1p13.1 (11) (12) (13) , which are designated type I and type II. Both genes consist in four exons and three introns, and both enzymes have high homology in their amino acid sequence (14, 15) . The type 1 gene (HSD3B1) is expressed in placenta, mammary gland, prostate, liver, kidney, and skin. The type II gene (HSD3B2) is expressed in the adrenal gland, ovary, and testis (16) .
The clinical presentation of HSD3B2 deficiency is heterogeneous and may range from salt-losing congenital hyperplasia (17) to premature pubarche, and mild hyperandrogenism (18) . However, the possibility that isolated abnormalities in male genital development, such as hypospadias, without other clinical manifestations, may be caused by a mutation in the HSD3B2 gene has not been documented up to now. We hypothesized that some cases of apparent idiopathic hypospadias may be consequence of HSD3B2 gene mutations, which may affect androgen production during fetal life. We conducted a prospective endocrine and molecular study in 90 patients with hypospadias with no evidence of salt loss during infancy, to determine the possible presence of molecular abnormalities in the HSD3B2 gene.
syndromes, or major anatomical abnormalities of the genitourinary or gastrointestinal tract were excluded. Some patients had additional evidence of ambiguous genitalia, such as cryptorchidism or micropenis. A complete physical examination was performed in each patient. Each parent gave signed informed consent, and the patient gave verbal assent when pertinent. The study was approved by the Ethics Committee of the San Borja Arriarán Hospital.
A standard ACTH stimulation test (Cortrosyn, 0.25 mg iv; Alliance Pharmaceutical, Whitshire, UK) was performed, and we determined the serum levels of 17OH Preg, 17OH Prog, cortisol, DHEA, and androstenedione before and 60 min after ACTH administration. In addition, a standard human chorionic gonadotropin (HCG) stimulation test (Profasi, 100 IU/kg im; Serono, Randolph, MA) was performed, and serum androstenedione, testosterone, and dihydrotestosterone were determined before and 24 h after drug administration. Baseline renin plasma activity was determined in most subjects, provided that they were resting comfortably for at least 30 min. DNA was prepared from peripheral leukocytes. A karyotype was performed in all subjects with hypospadias associated with bilateral cryptorchidism.
Hormone assays
To measure 17OH Preg, the sera were extracted with ethyl acetate: n-hexane (6:4, vol:vol) and purified in LC-18 columns by sequential elution with iso-octane:ethyl acetate (8:2 and 6:4, vol/vol), evaporated, and dissolved in PBS. The recovery was approximately 90%. A competitive binding RIA for 17OH Preg using antibody, tracer, and standards from ICN Pharmaceuticals (Costa Mesa, CA) was used to measure the extracted samples. The interassay coefficient of variation (CV) and intraassay CV were 10.1% and 8.3%, respectively.
Testosterone, dihydrotestosterone, androstenedione, 17OH Prog, cortisol, and DHEA were measured by competitive specific-binding RIAs (Diagnostic System Laboratories, Webster, TX); interassay CVs were 8.1, 6.2, 8.9, 7.3, 5.2, and 7.7%, respectively; the intraassay CVs were 5.3, 5.5, 4.2, 7.7, 3.1, and 5.3%, respectively. Plasma renin activity was measured using ␥ Coat Plasma Renin Activity 125 I RIA Kit (DiaSorin, Stillwater, MN), with inter-and intraassay CVs less than 10%.
The hormonal results in our patients were compared with the normal levels published in Normative Data for Adrenal Steroidogenesis in Healthy Pediatric Population from Lashansky et al. (19) .
Molecular methods
Selective PCR amplification of the HSD3B2 gene fragments, denaturing gradient gel electrophoresis (DGGE), and direct sequencing of PCR products. Genomic DNA of all subjects was extracted from peripheral blood by the method of Lahiri and Nurnberger (20) . The coding regions and the exon (ex)-intron (intr) splicing junction boundaries of the four exons of HSD3B2 gene were completely amplified by PCR, using six specific primer pair sets with GC-clamp attached at the 5Ј end as indicated in Table 1 , according to Marui et al. (21) . The existence of a unique band was evidenced in 1% agarose ethidium bromide-stained gel. The mutations were screened by DGGE in the conditions indicated in Table 1 , and the bands were evidenced by silver nitrate stain. All the patient samples were run by DGGE in parallel with negative and positive controls when they were available. The positive controls consisted of patients with known mutations in exon 4 (18) , kindly provided by Dr. Berenice Mendonca (Hospital das Clinicas, Sao Paulo, Brazil). The PCR fragments with abnormal electrophoretic migration in DGGE gels were again amplified from genomic DNA, purified using QIAquick PCR Purification Kit (QIAGEN Inc., Valencia, CA), and sequenced with additional internal primers in ABI PRISM model 310 version 3.4 automatic sequencer (Perkin-Elmer Cetus, AT). In addition, in the samples with abnormal migration, an allele-specific PCR was performed.
Genomic DNA was also obtained from 101 healthy fertile men, amplified, and resolved in the DGGE in parallel with the subjects and positive control samples. This process enabled us to determine the normal electrophoretic migration pattern by DGGE.
Site-directed mutagenesis
We generated vectors carrying the identified mutations using sitedirected mutagenesis. (QuikChange Site-Directed Mutagenesis Kit; Stratagene Cloning System, La Jolla, CA) following the manufacturer instructions. Briefly, the point mutations documented by sequencing were included in oligo sequences designed such that the desired nucleotide change was in the middle of the primer with at least 15 bases of correct sequence on each side. The point mutation was introduced into pcDNA3 human type II 3␤-HSD (kindly donated by Drs. Anne-Marie Moisan and Jacques Simard, University of Laval, Quebec, Canada) using Pfu Turbo DNA Polymerase that replicates both plasmid DNA strands. The product was treated with DpnI endonuclease selecting the mutated synthesized DNA. The DNA sequence of the newly introduced mutation in pcDNA3 type II 3␤-HSD was confirmed by double-strand DNA sequence analysis or by PCR amplification followed by DGGE of linearized mutated vector. MD) supplemented with 10% charcoal-stripped fetal bovine serum, 2 mmol/liter glutamax-I (GibcoBRL), 18 mm NaHCO 3 , 0.25 g/ml fungizone (GibcoBRL), 100 IU/ml penicillin, and 5 mg/ml streptomycin (Sigma Chemical Co., St. Louis, MO) at 37 C in 5% CO 2 /air in humidified atmosphere until confluence. Cells were plated in six-well plates at a density of 300,000 cells/well and were allowed to settle for 2 d. Medium was changed to free serum-DMEM media. Transient transfections of wild-type human type II 3␤-HSD and mutated type II 3␤-HSD were performed using Lipofectamine Plus Reagent (GibcoBRL) according to the manufacturer's instructions. For heterozygous mutations, the transfection was performed with equimolar concentrations of wild-type human type II 3␤-HSD and mutant vectors. Transfection efficiency was monitored by cotransfection of a ␤-galactosidase expression vector, and the activity was assessed by in situ ␤-galactosidase staining of transfected cells. To ascertain the amount of translated wild-type human type II 3␤-HSD and mutant recombinant proteins in transfected cells, 50 g of total proteins was size-separated by electrophoresis on a SDS-12% polyacrylamide gel and transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Inc., Richmond, CA). Briefly, filters blocked with 5% solution of BLOT-Quick Blocker (Chemicon International, Inc., Temecula, CA) in Tris-buffered saline (TBS)-0.1% Tween 20 (pH 7.6) and washed in TBS-0.1% Tween 20 were incubated with a polyclonal antibody (1:100) directed against human 3␤-HSD (kindly provided by Dr. Van Luu-The, University of Laval) for 2 h at room temperature, washed, and incubated with goat antirabbit IgG peroxidase-conjugated secondary antibody (1:10,000; Chemicon) for 1 h at room temperature. After washes, the positive bands were visualized using the Renaissance Plus Detection kit (NEN Life Science, Boston, MA) followed by exposure of the membranes to x-ray film for 10 sec.
Transfection of COS 7 cells and Western immunoblot analysis

Assay of 3␤-HSD enzymatic activity
The enzymatic activity of 3␤-HSD was determined by the conversion of DHEA to androstenedione by RIA. Briefly, 43 h after transfection, intact transfected COS-7 cells were incubated with 10 nm DHEA (Sigma) for 30, 90, and 360 min in serum-free DMEM media. Subsequently, we determined the concentration of DHEA and androstenedione by RIA in the media as indicated above. Results were normalized by protein concentration determined by BCA protein Assay Kit (Pierce, Rockford, IL).
Statistical analysis
Data are reported as mean Ϯ sem of serum determinations performed in duplicate, or of culture media of at least two separate transfection experiments in duplicate.
Results
The 90 subjects studied were classified based on their genital abnormalities. Fifty-nine subjects had isolated hypospadias, six had hypospadias and bilateral cryptorchidism, four had hypospadias and unilateral cryptorchidism, eight had hypospadias and micropenis, and 13 had severe hypospadias with bifid scrotum and chordee. The hypospadias was classified as penile in 71 and perineoscrotal in 19 patients. The average age at the time of the study was 6.0 Ϯ 0.4 yr, with a range of newborn to 15 yr. The patients' weight was 0.1 Ϯ 0.2 sd, and their height was Ϫ0.2 Ϯ 0.2 sd for chronological age. Surgery for correction of hypospadias was performed in 69 patients, with a single operation in 43 patients and two or more surgeries in 26. Twenty-one patients had not been subject to surgery at the time of the study, mostly because of their young age. Karyotype was 46 XY in all patients studied. The results of the hormonal profile obtained during the ACTH and HCG tests were within the normal range. Specifically, we did not observe definite evidence of a steroidogenic profile suggestive of 3␤-HSD, 17 ketoreductase, 5-␣ reductase deficiency, or androgen insensitivity in the 90 patients studied. Table 1 . DGGE revealed an abnormal migration pattern (arrows) of exon 4 in the 4em fragment in patient 1, 4gh fragment in patient 3, and 4ij fragment in patients 2, 4, and 5; of exons 1 and 2 in patients 6, 7, 8, and 9 and in control 1; and of exon 3 in control 2. The gels are representative of three separate PCR amplifications. For description of the fragments, see Table 1 . P, Patient; Ϫ, negative control; ϩ, positive control; C, fertile control with abnormal DGGE pattern.
Identification of HSD3B2 gene mutations in patients and control samples
Exons 1-4 were amplified using the primers described in Table 1 . The amplified PCR products were analyzed by DGGE, allowing rapid screening for mutations. With this method, we identified an altered electrophoretic mobility pattern by DGGE in four patients and one control for intron 1, and in five patients for exon 4 (Fig. 1) . In addition, an abnormal electrophoretic migration pattern for exon 3 was observed in one control.
To identify possible specific mutations responsible for the abnormal patterns in DGGE, the HSD3B2 gene was determined by sequencing in both directions in these five patients. Sequencing studies revealed the following heterozygous mutations: in patient 1, the G3 C transition predicts a modification of codon 213 (AGT) encoding Ser into Thr (ACT); whereas in patient 2, the nucleotide transition of C3 G predicts a change in codon 284 (AGC) encoding Ser into Arg (AGG). These findings were confirmed by allele-specific PCR. In the other three patients, the nucleotide transition did not predict an amino acid change in the primary structure of the enzyme. In patient 3, the substitution of T3 C at codon 238 (GCT) codes for the same amino acid Ala (GCC). Patient 4 showed an G3 A substitution in codon 259 (ACG), which encodes for the same amino acid Thr (ACA) and, in patient 5, the nucleotide substitution A3 C at codon 320 (ACA) codifier for the same amino acid Thr (ACC) (Fig. 2) . We observed an abnormal DDGE pattern in patients 6, 7, and 8 consisting of an heterozygous T3 G substitution in nucleotide 1362 of intron 1. In addition, patient 9 showed a heterozygous A3 C substitution in nucleotide 1372 of intron 1 (Fig. 2) .
In addition, we studied the four exons of the HSD3B2 gene by DGGE in DNA obtained from 101 healthy fertile men. Two control samples showed abnormal electrophoretic mobility by DGGE. One control sample (control 1) showed the same abnormal DGGE migration pattern in exons 1 and 2 as patients 6, 7, and 8 (Fig. 1) ; and the sequencing of the PCRfragment confirmed the same heterozygous T3 G substitution change in nucleotide 1362 of intron 1 (Fig. 2) . The other control sample (control 2) showed an abnormal DGGE pattern in exon 3 ( Fig. 1) , and sequencing identified a G3 A substitution at codon 78 (GTC) that encoded Val into I1e (ATC) in one allele (Fig. 2) .
FIG. 2.
Direct sequence analysis of the amplified spanning exons 1 and 2, exon 3, and exon 4 of HSD3B2 from patients and controls with abnormal DGGE patterns. Direct sequencing of exon 4 of patients 1, 2, and 5 (upstream primers) and patients 3 and 4 (downstream primers) showed heterozygous substitution (arrows); of exon 1 and 2 of patients 6, 7, 8, and 9 and in control 1 (upstream primer) and heterozygous substitution (arrows); of exon 3 of control 2 (upstream primer). Results represent at least four separate sequencing experiments in both directions with internal primers of purified PCR fragments for exon 4 and at least two separate sequencing experiments in both directions of purified PCR fragments for exon 1 and 2, and exon 3.
The clinical, hormonal, and molecular characteristics of the nine patients with changes in HSDB2 are shown in Tables 2  and 3 . We should note that patient 4 was diagnosed with bilateral Wilms' tumor at the age of 2 yr 8 months, with no known family history for this condition. The genetic analysis of WT1, kindly performed by Dr. Vicky Huff (Department of Molecular Genetics/Cancer Genetics, M. D. Anderson Cancer Center, Houston, TX), did not detect any mutations of this gene.
Family studies
PCR amplification and DGGE for exons 1, 2, 3, and 4 of the HSD3B2 gene were performed in DNA obtained from the parents and siblings in eight of the nine patients (Fig. 3) . DGGE analysis was performed in parallel with negative and positive controls, when the relatives were available for study. All samples with an abnormal DGGE pattern were sequenced. The family of patient 1 consists of both parents and a brother, and we documented that the mother and the brother, who had normal external genitalia, were also heterozygous for the S213T mutation, explained by possible phenotypic heterogeneity. The parents of patient 2 did not carry the S284R mutation, suggesting a de novo mutation. The mother of patient 3 did not carry the A238 mutation, and the father was not available for study. Both parents and a brother of patient 4 did not show any abnormality, indicating a de novo T259 mutation in this patient. The study of both parents and three siblings of patient 5 detected the T320 mutation only in the father, who showed a bifid prepuce and a wide urethral meatus. The family of patient 6 consists of both parents, a brother, and a sister, with the father showing the same n1362 T3 G heterozygous mutation. The father of patient 7 was also heterozygous for this mutation, whereas the mother did not show the nucleotide change, and his sister was not available for study. The family of patient 8 was not available for study. Finally, the family of patient 9 consists of To covert ng/ml in nmol/liter, multiply by the following factors: 17OH Preg ϫ 3.01, 17OH Prog ϫ 3.00, DHEA ϫ 3.47, and androstenedione ϫ 3.49.
a These ratios are obtained from the steroid values of 60 min after ACTH administration.
both parents and a sister; the patient and sister carried the n1362 T3 G substitution in intron 1, whereas the mother was normal, and the father was not available for study.
Effect of mutations on type II 3␤-HSD activity
To assess the influence of the mutations on type II 3␤-HSD expression and/or activity, COS-7 cells were transfected with the pcDNA3 vector containing wild-type human type II 3␤-HSD or mutant type II 3␤-HSD-S213T, -S284R, or -V78I variants alone or in equimolar concentrations with the wildtype human type II 3␤-HSD. Because an equal amount of each vector was transfected, we assumed that the enzyme expression was 50% from the wild-type vector and the other 50% from the variant. This was not confirmed by other methods, however. In support of this assumption, transfected cells expressed comparable amounts of either normal or mutated type II 3␤-HSD, and COS-7 cells did not express endogenous enzyme, as determined by Western immunoblotting (Fig.  4A) . The type II 3␤-HSD activity, studied by the conversion of DHEA to androstenedione, in transfected mammalian nonsteroidogenic cells with the vector expressing heterozygous S213T or S284R mutants, was reduced by 40 and 32%, respectively, compared with wild-type human type II 3␤-HSD (Fig. 4B) . The heterozygous V78I mutation detected in exon 3 of the control subject did not affect enzyme activity, as shown in Fig. 4B . In the cells transfected with the vector expressing the homozygous S213T, S284R, or V78I mutants, the enzyme activity was reduced by 96, 80, and 99%, respectively, compared with transfected cells with the wild-type human type II 3␤-HSD vector (Fig. 4B) .
Discussion
The first cases of HSD3B2 deficiency were described by Bongiovanni (22) . During the neonatal period, ambiguous genitalia with or without salt loss may be seen in both sexes (2, (23) (24) (25) (26) . Male newborn patients with mutations of the HSD3B2 gene may manifest salt-losing congenital adrenal hyperplasia, with undermasculinized genitalia resulting from the lack of secretion of mineralocorticoids and glucocorticoids by the adrenals, and of androgens by the testis. Older boys may show precocious pubarche, and varying degrees of hypogonadism may be observed during adolescence (1-3). Some patients with less severe mutations in HSD3B2 gene may show evidence of virilization during childhood or adolescence, without salt loss. In girls, precocious pubarche, abnormalities of pubertal development, and hyperandrogenism may be observed (2, 3, 27) .
In this study, we have shown that two patients with hypospadias have an heterozygous missense mutation in the HSD3B2 gene, causing a partial loss of enzymatic activity. These patients showed a normal steroidogenic metabolite response to ACTH and a normal androgen response to HCG. In vitro assays revealed a moderate decrease in 3␤-HSD activity in the heterozygous state, suggesting that this molecular abnormality may affect enzyme function. It is possible that during the first trimester of gestation, a critical period for the development of male external genitalia, this mutation may interfere with the migration of the urethral meatus to the tip of the glans penis. Direct confirmation of this hypothesis, however, cannot be concluded from this study.
We observed an S213T mutation in patient 1, and our in vitro studies demonstrated that this mutation reduced in vitro enzyme activity. The mother and the brother of this patient, however, harbored the same heterozygous mutation but did not exhibit any signs of 3␤-HSD deficiency. Thus, it is unclear whether this mutation caused the hypospadias in our patient. Moisan et al. (18) reported a mutation S213G in this same codon, in a girl with premature pubarche. We should mention that serine in codon 213 is conserved in primates and porcines but not in other species; whereas in nonprimates, species a threonine is not observed in this codon (28, 29) .
The S284R mutation harbored by patient 2 is located in a conserved hydrophobic domain localized between amino acids 283 and 310 in the COOH-terminal. The deletion of this region produces a mutant cytosolic enzyme that lacks a targeting sequence that directs the translated protein to specific organelles, so a mutation of this hydrophobic domain may be critical for subcellular localization (28 -30) .
Patients 3, 4, and 5 carried heterozygous silent mutations in exon 4, which might be polymorphic variants of the HSD3B2 gene. In our 101 healthy fertile control men, however, no polymorphic changes were observed in exon 4, although we documented a V78I heterozygous mutation in exon 3 in one control individual that displayed normal enzymatic in vitro activity. The number of control individuals we studied, though, is not sufficient to define with certainty the genotype distribution.
The fact that patient 4 developed a bilateral Wilms' tumor after our study was performed opens the question of whether his hypospadias was caused by a WT1 gene mutation (31) (32) (33) . Hypospadias has been observed in patients with Wilms' syndrome attributable to WT1 gene abnormalities, even without Wilms' tumor or overt nephropathy. The molecular study of the WT1 gene, however, did not show mutations of this gene in this patient.
An n1362T3 G substitution was observed in intron 1 in patients 6, 7, and 8 and in one healthy fertile control. The fathers of patients 6 and 7 harbored the same nucleotide substitution but had a normally located urethral meatus. Patient 9 showed heterozygous n1372A3 C mutation in intron 1, which was also carried by his father and sister, who did not exhibit genital anomalies. These substitutions in intron 1 are likely to represent polymorphisms. Both nucleotide changes in the intron 1 detected in this study are highly conserved through the human 3␤-HSD gene family. Simard et al. (34) reported two sibs with nonsalt-losing form of classic 3␤-HSD, who had a nucleotide mutation n6651G3 A in intron 3 in one allele, and a missense mutation in exon 4 in the other allele, which reduced enzymatic function. Some intronic nucleotide mutations may affect mRNA processing by modification of splicing sites. Previously, it has been reported that a complex dinucleotide repeat in the HSD3B2 located in the intron 3 constitutes a highly polymorphic region with variable racial/ethnic distribution (35) . The present study is the first report of nucleotide changes in intron 1 of this gene.
The hormonal abnormalities observed in patients with classical 3␤-HSD deficiency show increased levels of 17OH Preg and DHEA and increased ratios of 17OH Preg/17OH Prog, 17OH Preg/cortisol, and DHEA/androstenedione (36). We did not observe increased 17OH Preg or DHEA concentrations either in the basal state or after stimulation with ACTH or HCG in our patients with mutations of the HSD3B2 gene, except possibly in patient 3. This is not totally unexpected, however, because there are several difficulties in establishing the criteria for the diagnosis of 3␤-HSD deficiency based on hormonal levels: the levels of 17OH Preg may not be elevated due to normal activity of the 3␤-HSD type I, which is present in other tissues such as skin and liver. In addition, normal hormonal levels vary with chronological age and have broad ranges at different ages (19) . Furthermore, Lutfallah et al. (37) studied 12 heterozygous carriers of severe HSD3B2 mutations, and these patients had normal hormonal findings; however, subtle clinical findings or 3␤-HSD in vitro activity were not reported in that study. Recently Lutfallah et al. (38) proposed new hormonal criteria for the diagnosis of 3␤-HSD deficiency. One of the limitations of our study is the lack of normal hormonal values for the ACTH and HCG tests from our own laboratory, which complicates the interpretation of these results.
In summary, we have performed a complete hormonal and molecular study of the HSD3B2 gene in a large group of patients with apparent idiopathic hypospadias. Two patients showed heterozygous missense mutations in exon 4, leading to decreased in vitro enzymatic activity, suggesting a possible cause of reduction in androgen synthesis during the first trimester of gestation. We conclude that subtle molecular abnormalities of the HSD3B2 gene may be observed in some patients with apparent idiopathic hypospadias but that this finding is uncommon.
